Entrada Therapeutics Expands Its Board Of Directors With The Appointment Of Dr. Maha Radhakrishnan

Entrada Therapeutics, Inc. has announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Dr. Radhakrishnan brings with her extensive leadership experience in the biopharmaceutical industry, along with a strong background in medical affairs and product development. Since August 2024, Dr. Radhakrishnan has been serving as an Executive Partner at Sofinnova Investments, a European venture capital firm focused on life sciences. In this role, she is responsible for conducting in-depth evaluations of clinical-stage assets across various therapeutic areas. 

She also provides strategic guidance to Sofinnova’s portfolio companies, particularly in areas such as product development and commercialization. Prior to joining Sofinnova, Dr. Radhakrishnan served as Group Senior Vice President and Chief Medical Officer at Biogen from January 2020 to March 2024. During her time at Biogen, she led the company’s global medical function and played a key role in shaping medical strategy and engagement worldwide.

Dipal Doshi, Chief Executive Officer at Entrada Therapeutics, stated, “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be invaluable as we quickly advance our novel Duchenne programs into multiple patient-focused clinical trials throughout this year.”

Dr. Radhakrishnan stated, “I’m honored to join the Board of Entrada as it advances its clinical-stage portfolio of Duchenne therapies and its growing pipeline of novel approaches for devastating diseases. The promising Phase 1 safety and target engagement data, along with the urgent need for new treatments, reinforce the potential of Entrada’s approach to change the lives of people living with Duchenne. I look forward to working with Dipal and the Board to help bring this new class of intracellular therapies to patients and families affected by Duchenne and other serious illnesses.”

Earlier in her career, Dr. Radhakrishnan held senior leadership positions at several major healthcare and pharmaceutical organizations. She served as Senior Vice President and Global Head of Medical for the Primary Care Business Unit at Sanofi, and before that, held important roles at Bioverativ (which was later acquired by Sanofi), Bristol Myers Squibb, UnitedHealth Group, and Cephalon (acquired by Teva Pharmaceuticals).

Dr. Radhakrishnan earned her M.D. in Internal Medicine with honors from the People’s Friendship University in Moscow, Russia. She also holds a Master’s degree in the Russian language. Her broad experience across medical, scientific, and strategic domains is expected to be a valuable asset to Entrada’s Board of Directors as the company advances its pipeline and business objectives.